EcoR1's Nodelman Lifts AnaptysBio Stake to 27.8% After $17.2M Buying Run
ANAB has more than doubled off its 52-week low of $22.063.
Summary
EcoR1 Capital and Oleg Nodelman disclosed a 27.8% AnaptysBio stake, 8,254,674 shares bought for $154.7 million cumulatively, after adding 374,580 shares for $17.2 million on November 16-18. The 13D/A also states Nodelman may push for board and management action, including a sale or change in control.
Key Events · Ownership and Investor Activity · ANAB
-
EcoR1 Stake Reaches 27.8%
EcoR1 Capital, Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. report beneficial ownership of 8,254,674 shares, 27.8% of the 29,729,847 shares outstanding as of November 9, 2026; the Qualified Fund alone holds 7,642,937 shares, or 25.7%.
-
$17.2M Added Over Three Days
The buying broke down as 84,120 shares at $45.6624 on 11/16, 152,367 at $45.6553 on 11/17 and 138,093 at $46.5419 on 11/18, totaling 374,580 shares for $17,224,592.78.
-
Cumulative Cost Basis $154.7M
For the 8,254,674 shares, the funds paid an aggregate $154,747,392.28, about $18.75 per share on average, against today's $47.74 price.
-
Board Seat With Action Rights
Item 4 states Nodelman is a director and the reporting persons may recommend action to management, the board and stockholders, potentially including mergers, asset sales, changes in control or capitalization changes; they report no present plan to do so.
Analysis · ANAB · Life Sciences
The headline number is the stake: EcoR1 Capital and Oleg Nodelman now hold 8,254,674 AnaptysBio shares, 27.8% of the 29,729,847 shares outstanding as of November 9, 2026, after buying 374,580 shares for $17.2 million on November 16-18. Those trades were already on the Form 4 filed earlier today, so what is new here is the size of the position and its cost: $154.7 million cumulatively, an average of roughly $18.75 a share, well below today's $47.74. That is a large, deeply profitable holder who also sits on the board. For governance, the Item 4 language is the part that matters: Nodelman may recommend actions to management, the board and stockholders, including mergers, asset sales, changes in control or capitalization changes. With a Delaware Chancery ruling on the dostarlimab contract dispute still pending per the Q3 10-Q, a 27.8% holder with board access has real leverage over whatever comes next.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $47.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.06 to $72.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.